SEC Tracker
Get the app

Braveheart Bio BRVE

Braveheart Bio shares positive phase 2 data for HRS/BHB-1893

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Routine
  1. 52-week study showed 79% of patients had LVOT gradient <30 mmHg
  2. Peak oxygen uptake increased by 2.7 mL/kg/min
  3. 57% of patients remained on 40 mg BID starting dose
  4. KCCQ-CSS improved by 17.3 points

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Braveheart Bio files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. America Great Health AAGH
  2. AbbVie ABBV public float $325.1B, Jun 30, 2025
  3. Abeona Therapeutics ABEO public float $273M, Jun 30, 2025
  4. Abbott Laboratories ABT public float $232.2B, Jun 30, 2025
  5. Arbutus Biopharma ABUS public float $472M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.